GloriaBio's Zimberelimab Experience Indicative Of China Commercial IO Challenges

 
• By Dexter Jie Yan
  
commercial setback
2022 saw the first major commercial setback for a biotech in China's burgeoning PD-1/L1 sector • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia